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Abstract
Introduction: Recent evidence suggests an interaction between bone metabolism
and blood pressure (BP) regulation. The aim of our study was to evaluate
endocrinological and metabolic factors related to pulse pressure (PP) in
normotensive, normolipidaemic, non-smoker subjects. 
Material and methods: We consecutively enrolled 156 adults (37 males, 
119 females) in summer 2009. The BP and body mass index (BMI) were recorded,
and serum samples were taken for 25-hydroxy vitamin D (25-OHD), insulin-like
growth factor-1 (IGF-1), growth hormone (GH), parathormone (PTH), calcium,
albumin, phosphorus, glucose, triglyceride and cholesterol levels.
Results: In the postmenopausal group, PP was significantly associated with age
and BMI, while in premenopausal patients it was inversely related to ionized
calcium. In men, a reverse relationship was present between GH and IGF-1 levels
and PP .
Conclusions: The PP was predicted by different parameters in different genders
and these predictors change even in the same gender before and after
menopause. Well-known predictors of PP such as age and BMI were more
pronounced in postmenopausal women, but none of the groups showed
a relationship between PP and 25-OHD or PTH.
Key words: vitamin D, blood pressure, insulin-like growth factor-1, calcium, body
mass index.
Introduction
Abundant recent evidence suggests a complex interaction between
bone metabolism and blood pressure regulation. A recent meta-analysis
of ten observational studies and nine randomized controlled trials supports
a relationship between high blood pressure and low vitamin D levels [1].
Parathyroid hormone (PTH) level is a known cardiovascular risk predictor
in patients with chronic renal disease (CRD) [2], but studies about its effect
on blood pressure in normal people are lacking. 
The relationship of insulin-like growth factor-1 (IGF-1), growth hormone
(GH) and blood pressure is based on observations in patients with
acromegaly and obstructive sleep apnoea syndrome [3, 4], but their
interrelationship in normal subjects is not clear. Some studies suggest an
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interaction between IGF and vitamin D metabolism:
active vitamin D (1,25-hydroxy-cholecalcipherol) may
increase IGF-1 receptors and IGF-1 may augment
renal 1-α hydroxylase expression, so increasing the
active form of vitamin D [5]. Meanwhile, insulin-like
growth factor binding proteins may interact with
vitamin D receptors, inducing the expression of
bone differentiation markers [6]. More recent
studies also show a relationship between vitamin D
and IGF-1 in metabolic syndrome patients [7]. 
There is also a strong association between serum
25-hydroxy vitamin D (25-OHD) levels and body
mass index (BMI): obese people have lower 25-OHD
levels than non-obese people [8]. Meanwhile,
recently it was observed with the calcium-citrate
clamping test that obese subjects have disturbed
calcium homeostasis that is very similar to that
related to compensatory mechanisms in patients
with early renal insufficiency, showing a left-sided
shift in the calcium-PTH curve, indicating a lower
set point, related to the duration of obesity [9]. But
still there is no practical application of this
knowledge. 
Pulse pressure (PP) is a non-invasively measured
parameter related to cardiovascular risk, showing
the difference between pulsatile stress of large
artery stiffness during systole and steady-state
stress of small vessel resistance during diastole [10].
The PP is calculated as the difference between
systolic and diastolic blood pressures and normally
it is 30-40 mmHg. Wider pulse pressure is a known
risk factor associated with higher mortality and
higher risk of myocardial infarction [11].
In this context, the aim of our study was to
evaluate endocrinological and metabolic factors
related to PP among genders in non-obese,
normotensive, non-smoking, non-diabetic subjects.
In particular, we aimed to test for any differences
between premenopausal and postmenopausal
women, and men, as regards calcium metabolism-
related parameters, IGF-1 and GH, and their
relationship with PP .
Material and methods
We enrolled 156 patients (37 men, 119 women;
41 postmenopausal and 78 premenopausal)
between 19 years and 70 years of age, without
hypertension, hyperlipidaemia, diabetes, peripheral
or coronary arterial disease in June-September 2010.
None of them was a smoker. All were normo  -
calcaemic and normoalbuminaemic. Patients using
vitamin or calcium preparations, or with renal or
hepatic disease, were excluded. Ethical Committee
approval was obtained from the local ethical
committee. The study was explained in detail to
each subject and informed consent was obtained
from each person. 
We recorded weight, height and blood pressure,
measured by a sphygmomanometer (Erka, Perfect
Aneroid with auto valve Sphygmomanometer, with
adult ‘size 4’ cuffs) and recorded in a sitting position
from both arms supported at heart level. The
measurements were repeated 3 times with
minimum 10-min intervals, and the mean value was
calculated. The PP was calculated as the difference
between systolic (SBP) and diastolic blood pressures
(DBP) [10]. The BMI was calculated as weight in
kilograms divided by square of height in metres
(kg/m2). 
Biochemical analysis
Venous blood samples were obtained early in
the morning for measuring 12-h fasting blood
glucose, total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, triglyceride, calcium, phosphorus,
ionized calcium, IGF-1, and PTH levels with lab kits
of USA origin. The PTH levels were measured by
electrochemiluminescence immunoassay (ECLIA,
Cobas®) [12] using an Elecsys 2010 analyser (USA)
with an inter-assay coefficient of variation below
or equal to 6.5%, and IGF-1 was measured by
immunoradiometric assay (IRMA, Immunotech) [13]
with an intra-assay coefficient of variation of below
or equal to 6.3% and an inter-assay coefficient of
variation of below or equal to 6.8%. 25-OHD
measurements were obtained by standard high-
performance liquid chromatography (HPLC,
Immündiagnostik) [14]. Growth hormone measure  -
ment was performed by the IRMA method
(Immunotech with inter-assay coefficient of
variation ≤ 14.0%). The other parameters were
measured by a standardized automatic colorimetric
method using the Cobas Integra 400 Analyzer
(USA). Tests were done immediately, just after
taking blood samples in the morning of the
patient’s visit to the ambulatory.
Statistical analysis
Patients were grouped as men, premenopausal
women and postmenopausal women. After
normality distribution testing by Kolmogorov-
Smirnov test, and parameter log-normalization
(when needed) the continuous variables of these
three groups were compared by ANOVA test
followed by post-hoc Tukey HSD test. Multiple
regression analysis was performed to determine the
parameters related to PP for each patient group
separately. A p  value < 0.05 was considered
significant for all tests. All statistical calculations
were executed by the program SPSS 15.0 (for Office).
Results
Among the 156 adults included in the study,
women (n = 119) were grouped in pre- and post  -
menopausal groups; thus we had 3 groups to
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compare. The mean and standard deviation of
measured parameters are summarized in Tables I
and II. 
We observed that age was significantly higher
in postmenopausal patients than all other groups
(men vs. postmenopausal women p < 0.05, post-
vs. pre-menopausal groups p < 0.05, men vs.
premenopausal group p  < 0.01). Also, BMI of
postmenopausal women was higher than that of
premenopausals (p < 0.05). Premenopausal women
had higher GH levels than men (p < 0.05) and
postmenopausals (p < 0.01). Premenopausal women
also had significantly lower triglyceride levels than
others (premenopausal group vs. men, p < 0.05;
pre- vs. post-menopausal women, p < 0.01) and HDL
levels were higher in the premenopausal group than
men (p < 0.01). Meanwhile premenopausal women
also had lower SBP than the other two groups 
(p = 0.001 for both), lower DBP than men (p < 0.01)
and postmenopausal women (p < 0.01), and also
lower PP than men (p < 0.01) and postmenopausals
(p < 0.01).
In the postmenopausal group, regression analysis
showed a significant relationship between PP and
age and BMI. In premenopausal patients, PP was
inversely associated with ionized calcium. In men,
IGF-1 and GH levels were inversely related to PP
(Table III).
Discussion
Blood pressure control is important for
cardiovascular risk reduction and usually studies
related to pulse pressure and systemic blood
pressure were carried out on hypertensive patients
[15]. In this study, we evaluated the association of
calcium metabolism-related factors, GH and IGF-1
with PP in normotensive subjects grouped as men,
and post- and pre-menopausal women. Higher
incidence of hypertension in postmenopausal
women with low bone density is well known, but
Parameter All patients† Pre-menopausal  Post-menopausal Men  Values of p
(n = 156) (n = 78) (n = 41) (n = 37) (ANOVA)**
Age [years] 41.9 ±1.3 35.2 ±8.4 51.6 ±4.7 46.0 ±12.5 0.001*
BMI [kg/m2] 27.62 ±5.3 26.4 ±5.5 29.2 ±3.8** 28.4 ±6.5 0.019*
25OHD [μg/l]) 24.5 ±12.8 22.22 ±12.54 25.60 ±13.20 27.40 ±11.83 NS
Serum calcium [mg/dl] 9.43 ±0.42 9.43 ±0.36 9.34 ±0.47 9.54 ±0.49 NS
Albumin [g/dl] 4.45 ±0.34 4.39 ±0.35 4.32 ±0.18 4.99 ±0.34 NS
Ionized calcium [mmol/l] 1.10 ±0.01 1.11 ±0.03 1.10 ±0.02 1.09 ±0.03 NS
Phosphorus [mg/dl] 3.41 ±0.48 3.43 ±0.44 3.45 ±0.46 3.31 ±0.54 NS
PTH [pg/ml] 51.18 ±20.6 52.00 ±19.82 53.32 ±24.32 47.40 ±18.47 NS
GH [ng/ml] 2.59 ±3.96 3.95 ±4.98** 1.16 ±0.74 1.62 ±2.98 0.001*
IGF-1 [ng/ml] 183.69 ±60.22 201.44 ±49.03** 153.59 ±49.24 174.07 ±80.36 0.001*
BMI – body mass index, 25OHD – 25-OH vitamin D, PTH - parathormone, GH – growth hormone, IGF-1 – insulin-like growth hormone-1, 
NS – statistically not significant, *p < 0.05 accepted as statistically significant, †all parameters are given as mean ± standard deviation, 
**see the text for significant differences between three groups (revealed by post-hoc Tukey HSD test), normal ranges of hormone levels are: 
PTH 11-54 pg/ml, 25OHD > 20 μg/l, IGF-1 90-300 ng/ml, GH < 5 ng/ml
Table I. Characteristics and biochemical parameters of the studied groups (mean ± SD)
Parameter All patients† Pre-menopausal  Post-menopausal Men  Values of p
(n = 156) (n = 78) (n = 41) (n = 37) (ANOVA)**
TG [mg/dl] 116.56 ±46.77 101.03 ±40.17** 140.63 ±55.61 123.83 ±37.92 0.001*
LDL-C [mg/dl] 121.01 ±27.10 118.05 ±28.77 127.76 ±21.73 119.37 ±29.18 NS
HDL-C [mg/dl] 54.59 ±15.14 58.67 ±14.79** 52.68 ±12.35 48.48 ±16.66 0.002*
SBP [mmHg] 123.3 ±12.8 117.6 ±10.2** 129.4 ±13.5 129.76 ±11.2 0.001*
DBP [mmHg] 77.9 ±9.5 75.0 ±9.1** 81.0 ±9.4 81.1 ±8.7 0.001*
PP [mmHg] 45.4 ±10.4 42.39 ±8.4** 48.3 ±10.7 48.85 ±12.7 0.001*
TG – triglycerides, LDL-C – low-density lipoprotein cholesterol, HDL-C – high-density lipoprotein cholesterol, SBP – systolic blood pressure, 
DBP – diastolic blood pressure, NS – statistically not significant, *p < 0.05 accepted as statistically significant, †all parameters are given as mean
± standard deviation, **see the text for significant differences between three groups (revealed by post-hoc Tukey HSD test)
Table II. Blood pressure and lipid parameters of the studied groups (mean ± SD)
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the effect of calcium metabolism-related factors on
blood pressure is not clear [16]. Vitamin D may have
a role in the association between atherosclerosis
and osteoporosis in this group of patients, but the
role of vitamin D in blood pressure levels in
normotensive subjects is not yet well known [17].
The PP is a marker of stiffening of large arteries
and is a well-known independent predictor of
cardiovascular risk [18-21]. Since stiffening of
arteries is related to age, in our study, in fact, we
observed a direct relationship between age and PP
in the postmenopausal group that has higher mean
age than both other considered groups. The same
group also had the highest BMI, which was also
consistent with literature data [22].
Since the pulsatile secretion of GH is more
important for evaluation, we measured IGF-1 levels
together with GH. Similarly, we recorded ionized
calcium levels of patients to avoid factors affecting
total serum calcium levels. Higher GH and IGF-1
levels in premenopausal women may parallel their
lower mean age as expected, but the reverse
relationship between IGF-1 and GH levels and PP in
men should be confirmed with physiological studies.
A negative relationship between adiposity and GH
[23, 24] may be a theoretical explanation, but in our
study men did not show a significant difference
from others regarding BMI. These findings on
relations between blood pressure and GH and IGF-1
levels are parallel with known observations in the
medical literature as observed in special patient
groups with acromegaly or sleep apnoea [3, 4].
Postmenopausal women with higher BMI did not
reveal any relationship between PP and GH or IGF-1,
probably because some other factors (such as age
and BMI found in this study) dominate. 
Ionized calcium and pulse pressure were
inversely related in premenopausal patients. There
are many studies related to calcium metabolism
and PP in chronic renal failure patients but not in
the healthy population [25, 26]. This younger and
relatively thinner group revealed lower systolic and
diastolic blood pressure and consequently lower
pulse pressure values than the other two groups.
In the study of Fraser et al., albumin adjusted
calcium levels were associated with higher systolic
blood pressure in three National Health and
Nutrition Examination Survey (NHANES) cycles [27].
While the above-cited meta-analysis of Feneis 
et al. [1] supported a significant association between
hypertension and low serum vitamin D, another
recent meta-analysis of 3 cohorts did not find
a significant association between vitamin D and
incident hypertension [28]. Thus, the medical
literature still has no consensus about the
relationship between calcium homeostasis and
cardiovascular outcomes. 
Our study also did not reveal a relationship
between PP and 25-OHD or PTH in pre- and post-
menopausal women or in men. In the study of Chan
et al. carried out on elderly men, PTH was
associated with blood pressure but serum 25-OHD
levels were not found to be related [29]. Similarly,
the study of Hjelmesaeth et al. also revealed an
association of metabolic syndrome and PTH levels
but not serum 25-OHD levels in morbidly obese
people [30]. 
Despite the fact that the study was executed in
summer, the mean 25-OHD level of patients in 
any group is slightly higher than the lower limit 
(i.e. 20 μg/l) suggested by the American Endocrine
Society [31]. Its role in the study results was
unpredictable. 
Although to the best of our knowledge in the
medical literature there is no other study comparing
healthy men and pre- and post-menopausal women
regarding pulse pressure and calcium metabolism
related parameters, our study still has some
restrictions. Firstly, the blood pressure measure  -
ments were not made by ambulatory 24-h
measurements, which may give more valuable and
detailed information including nocturnal changes.
Secondly, although we compared three groups, the
relatively low number of males may restrict the
evaluation of gender differences. And since it is
a cross-sectional study, we cannot speculate on
Factor Value of β Value of p 95% CI upper bound 95% CI lower bound
Postmenopausal women
Age 0.228 0.024 0.03 0.425
BMI 0.390 0.035 0.028 0.751
Premenopausal women
Ionized calcium –85.568 0.008 –148.21 –23.115
Men 
IGF-1 –0.081 0.004 –0.134 –0.028
GH –1.615 0.036 –3.112 –0.118
Table III. Factors that were significantly related to pulse pressure in regression analysis for each group
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future results of vitamin D status, or effects of
treatment. Meanwhile, GH is affected by many
factors and its spot measurement may not suggest
specific pathology unless it exceeds a threshold,
but we also measured and included IGF-1 to avoid
misleading results due to fluctuations in GH levels. 
In conclusion, in our normotensive, non-smoker,
non-diabetic, normolipidaemic study group, PP was
related to age and BMI in postmenopausal women,
inversely related to ionized calcium in premeno  -
pausal women and also inversely related to IGF-1
and GH in men, and none of the groups showed
a relationship between PP and 25-OHD or PTH. That
suggests changing dynamics of the relationship
between PP and GH, IGF-1 and calcium metabolism
markers according to gender, age, BMI and also
menopausal status.
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